EGFR and non-small cell lung carcinoma: Afatinib was specially designed against the EGFR secondary mutation T790M and was approved for patients with metastatic non-small cell lung cancer (NSCLC), whose tumors have deletions on epidermal growth factor receptor (EGFR) exon 19 or exon 21 (L858R) substitution mutations [19].